CX3CL1 and Mental deterioration: Levels of soluble CX3CL1 correlate with cortical synapse density, and cerebrospinal fluid concentrations predicting cognitive decline over three-year period in the ENCORE-HD trial cohort, positioning CX3CL1 as both a biomarker and a therapeutic target (Figure 5A).